Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
Interventions: Erlotinib (tarceva), Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more

Conditions: Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer, Genital Warts, Oropharyngeal Cancer
Interventions: Simple Reminder; Behavioral
Lead sponsor: Regenstrief Institute, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 1,305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Epilepsy, Seizures, Epileptic
Interventions: SPN-817; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: Alport Syndrome
Interventions: BAY 3401016, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Miami, Florida • Chubbuck, Idaho + 2 more

Conditions: Healthy, Strabismus
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: Non-Interventional; Other
Lead sponsor: AIQ Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Madison, Wisconsin

Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
Interventions: Vitamin D, Rituximab, Placebo; Dietary Supplement · Biological · Other
Lead sponsor: Jonathan Friedberg; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 4 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Total Hip Replacement (Non-inflammatory)
Interventions: Novation Ceramic; Device
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Cumming, Georgia • Worcester, Massachusetts + 2 more

Conditions: Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Months to 20 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 46
States / cities: Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more

Conditions: Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy
Interventions: Lotrafilcon A contact lenses, Balafilcon A contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Delray Beach, Florida • St Louis, Missouri • Fort Worth, Texas

Conditions: Small Cell Lung Cancer
Interventions: pemetrexed, etoposide, carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 54
States / cities: Huntsville, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 51 more

Conditions: Jaw, Edentulous, Partially
Interventions: OsseoSpeed™, NobelSpeedy™ Replace®, NanoTite™ Certain® PREVAIL®; Device
Lead sponsor: Dentsply Sirona Implants and Consumables; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Iowa City, Iowa • Chapel Hill, North Carolina • Houston, Texas

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Interventions: trastuzumab, paclitaxel, recombinant interleukin-12; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anorexia Nervosa
Interventions: Fecal Microbiota Transplantation (FMT); Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Diabetes Mellitus
Interventions: Shared Medical Appointments; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Peripheral Vascular Disease
Interventions: Omnilink Elite™ Peripheral Balloon-Expandable Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Out-Of-Hospital Cardiac Arrest
Interventions: Placebo, sodium nitrite 45 mg, sodium nitrite 60 mg; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Subjects
Interventions: PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer
Interventions: Afuresertib, Carfilzomib; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cary, North Carolina

Search by objective public record fields.

PiMZ Longitudinal Cohort (PiMZ Logic)

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye

TRAQinform Assessment of Immunotherapy Response

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

The Genetic Basis of Atrial Fibrillation (AF)

Post Approval Study: NOVATION Ceramic Articulation Hip System

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

Air Optix® Night and Day® Aqua Therapeutic Wear

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Study Comparing Appearance and Function of Three Different Dental Implant Designs When Placed in Front Region of Upper Jaw

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Improving Medical Training for the Care of Chronic Conditions

Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery

Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)